Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of selonsertib in moderate to advanced diabetic kidney disease
MOH_2019-10-31_007466Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis comparing Selonsertib with Placebo (2 arms). Primary endpoint: Clinical event-driven kidney outcome. Started Sep 2019; status: completed.
02
Drugs
selonsertib
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on MOH_2019-10-31_007466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-31_007466.